The University of Oxford, in partnership with the Ellison Institute of Technology (EIT), announced on September 1, 2025, the launch of a large-scale research program on the application of AI in vaccine development. The program, funded by EIT with up to £118 million, is named CoI-AI (Correlates of Immunity-Artificial Intelligence). Its goal is to combine Oxfords expertise in immunology and clinical trials with EITs cutting-edge AI technologies. Scientists will use machine learning to analyze vast datasets from human challenge studies to pinpoint the exact immune responses that protect the body from pathogens. This will not only accelerate the creation of new vaccines against antibiotic-resistant bacteria but also lay the foundation for "programmable" immunology, where vaccines can be designed faster and more accurately. This project marks a new era in biomedical research, with AI becoming a key tool for solving the most complex healthcare challenges.
Oxford and Ellison Institute Launch £118M AI Vaccine Development Program
